Scarica l'app Stockscreener
772.00
5.85%
-49.46
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$821.46
Aprire:
$816.89
Volume 24 ore:
3.28M
Relative Volume:
0.90
Capitalizzazione di mercato:
$737.81B
Reddito:
$49.00B
Utile/perdita netta:
$11.11B
Rapporto P/E:
62.82
EPS:
12.29
Flusso di cassa netto:
$-1.27B
1 W Prestazione:
-12.63%
1M Prestazione:
+4.77%
6M Prestazione:
-0.38%
1 anno Prestazione:
+0.88%
Intervallo 1D:
$772.04
$818.42
Intervallo di 1 settimana:
$772.36
$902.50
Portata 52W:
$677.09
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Confronta LLY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
772.16 | 737.81B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
154.61 | 370.90B | 89.33B | 21.81B | 18.57B | 8.99 |
|
ABBV
Abbvie Inc
|
187.04 | 340.25B | 57.37B | 4.20B | 17.83B | 2.35 |
|
NVO
Novo Nordisk Adr
|
66.24 | 277.97B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
NVS
Novartis Ag Adr
|
111.06 | 222.45B | 53.22B | 12.86B | 14.85B | 6.39 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Eli Lilly (LLY) Raises Dividend by 15%, Maintains Shareholder Payout for 55th Consecutive Year - TipRanks
Eli Lilly Stock Plunges: LLY Shares Dive Nearly 3% in Morning Trading - paginasiete.bo
Eli Lilly Stock Slips on Outlook. Is It Time to Buy the Dip? - The Motley Fool
Eli Lilly (LLY) Partners with Alchemab on ALS Drug Development - GuruFocus
Lilly to Break Ground on $4.5 Billion Medicine Foundry in Lebanon - WIBC
Why Viking Therapeutics Stock Surged Nearly 20% Higher in April - The Motley Fool
Alchemab Therapeutics signs landmark $415m licensing agreement for ATLX-1282 with Eli Lilly and Company - PrimePublishers.com
Lilly to break ground on $4.5 billion medicine foundry in Lebanon - WISH-TV
Eli Lilly (LLY) Maintains Quarterly Dividend at $1.50 Per Share - GuruFocus
Eli Lilly announces $1.50 Q2 dividend per share By Investing.com - Investing.com India
Eli Lilly announces $1.50 Q2 dividend per share - Investing.com
Lilly declares second-quarter 2025 dividend - Quantisnow
LLY stock news: Eli Lilly Declares $1.50 Quarterly Dividend - paginasiete.bo
Lilly declares second-quarter 2025 dividend | Eli Lilly and Company - Eli Lilly and Company
Eli Lilly & Co. (LLY) Declares $1.50 Quarterly Dividend; 0.7% Yield - StreetInsider
Eli Lilly Sets $1.50 Per Share Dividend Payout: Key Dates and Details for Q2 2025 - Stock Titan
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know - Yahoo Finance
Eli Lilly’s Strategic Adjustments and Growth Prospects Reinforce Buy Rating Despite Setbacks - TipRanks
Eli Lilly First Quarter 2025 Earnings: EPS Misses Expectations - Yahoo
This pill could forever change how people lose weight3 May 2025Time Magazine EuropeReadly | All magazines - Readly | All magazines - one magazine app subscription
Eli Lilly and Company (NYSE:LLY) Q1 2025 Earnings Call Transcript - Insider Monkey
Eli Lilly (LLY) Stock Rating Maintained by UBS Despite Price Tar - GuruFocus
Eli Lilly (NYSE:LLY) Announces Promising Trial Data And Updates 2025 Guidance - Yahoo Finance
UBS cuts Eli Lilly stock target to $1,050, maintains Buy rating - Investing.com UK
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday - AOL.com
Eli Lilly’s Stock Selloff Is Overdone, Analysts Say. Here’s Why. - MSN
Cantor Fitzgerald maintains $975 target on Eli Lilly stock By Investing.com - Investing.com India
Cantor Fitzgerald maintains $975 target on Eli Lilly stock - Investing.com
Eli Lilly Stays Strong Despite CVS Dropping Key Drug - Finimize
Leerink sees Eli Lilly stock dip as buying chance, keeps $944 target - Investing.com India
Eli Lilly stock sell-off was 'overreaction': Analysts - Yahoo Finance
Is the Trump Administration About to Cause AbbVie, Eli Lilly, and Johnson & Johnson Stocks to Crash? - AOL.com
Lilly to participate in Bank of America Securities 2025 Healthcare Conference - Quantisnow
Eli Lilly CFO to Share Strategic Insights at Major Bank of America Healthcare Conference - Stock Titan
Positive Outlook for Eli Lilly & Co. Despite Competitive Challenges - TipRanks
Eli Lilly (LLY) Price Target Reduced by UBS Analyst Despite Stro - GuruFocus
Eli Lilly (LLY) sell-off 'overdone' on CVS move on WegovyLeerink - StreetInsider
Eli Lilly Tackles CVS Health's Cut In Zepbound Coverage - Finimize
Street View: Eli Lilly well positioned in weight-loss market despite CVS's decision - TradingView
Eli Lilly selloff on CVS Wegovy news overdone, says JPMorgan - TipRanks
Eli Lilly & Co: Strong Market Position and Growth Potential Amid Competitive Pressures - TipRanks
Decoding Eli Lilly and Co (LLY): A Strategic SWOT Insight - GuruFocus
Eli Lilly and Co (LLY) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic ... - Yahoo Finance
Eli Lilly and Co (LLY) Q1 2025 Earnings Call Highlights: Record Revenue Growth and Strategic Innovations - GuruFocus
Eli Lilly (LLY) Faces Market Cap Drop Amid Competitive Pressure - GuruFocus
Eli Lilly (LLY) Prepares for Potential Tariffs on Pharmaceuticals - GuruFocus
Eli Lilly sales soar 45% on weight loss drug demand, but drugmaker cuts profit outlook after cancer treatment deal - MSN
Eli Lilly downplays CVS move to drop Zepbound coverage, shares plunge - Reuters
Friday Five – Pharma's tariff-proofing playbook, Novo slims Lilly's lead, vaccine policy shakeup…and more - FirstWord Pharma
Obesity Drug Price Wars Heating Up as CVS Picks Novo Over Lilly - Bloomberg.com
Lilly Cuts Earnings Guidance on Research Charges, Shares Fall - Bloomberg.com
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.20%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):